# ESMO-MCBS Evaluation Form - HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide v0.1.0

* [**Table of Contents**](toc.md)
* [**Artifacts Summary**](artifacts.md)
* **ESMO-MCBS Evaluation Form**

## CodeSystem: ESMO-MCBS Evaluation Form 

| | |
| :--- | :--- |
| *Official URL*:https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form | *Version*:0.1.0 |
| Active as of 2026-05-21 | *Computable Name*:EsmoMcbsEvaluationForm |

 
The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale 

 This Code system is referenced in the content logical definition of the following value sets: 

* [EsmoMcbsEvaluationForm](ValueSet-sact-esmo-mcbs-evaluation-form.md)



## Resource Content

```json
{
  "resourceType" : "CodeSystem",
  "id" : "sact-esmo-mcbs-evaluation-form",
  "url" : "https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form",
  "version" : "0.1.0",
  "name" : "EsmoMcbsEvaluationForm",
  "title" : "ESMO-MCBS Evaluation Form",
  "status" : "active",
  "date" : "2026-05-21T02:29:02+00:00",
  "publisher" : "Te Aho o Te Kahu, Cancer Control Agency",
  "description" : "The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale",
  "content" : "complete",
  "count" : 12,
  "concept" : [{
    "code" : "ST-1a",
    "display" : "Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies"
  },
  {
    "code" : "ST-1b",
    "display" : "Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting"
  },
  {
    "code" : "ST-2a",
    "display" : "Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"
  },
  {
    "code" : "ST-2b",
    "display" : "Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"
  },
  {
    "code" : "ST-2c",
    "display" : "Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"
  },
  {
    "code" : "ST-3",
    "display" : "Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"
  },
  {
    "code" : "HM-1a",
    "display" : "Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies"
  },
  {
    "code" : "HM-1b",
    "display" : "Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies"
  },
  {
    "code" : "HM-2a",
    "display" : "Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"
  },
  {
    "code" : "HM-2b",
    "display" : "Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"
  },
  {
    "code" : "HM-2c",
    "display" : "Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"
  },
  {
    "code" : "HM-3",
    "display" : "Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"
  }]
}

```
